99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies
Evaluation of efficacy of anti-cancer therapy is currently performed by anatomical imaging (e.g., MRI, CT). Structural changes, if present, become apparent 1–2 months after start of therapy. Cancer patients thus bear the risk to receive an ineffective treatment, whilst clinical trials take a long ti...
Main Authors: | Chris P. Reutelingsperger, Frédéric L.W.V.J. Schaper |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/5/2/550 |
Similar Items
-
Preliminary Biological Evaluation of Novel 99mTc-Cys-Annexin A5 as a Apoptosis Imaging Agent
by: Zichun Hua, et al.
Published: (2013-06-01) -
Patient-specific dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in children
by: Xinchi Hou, et al.
Published: (2017-10-01) -
99mTc-Hynic-TOC imaging in the diagnostic of neuroendocrine tumors
by: Knut Liepe, et al.
Published: (2018-01-01) -
99mTc-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients: a proof-of-concept study
by: Eef D. Telenga, et al.
Published: (2019-05-01) -
Early detection of steroid-induced femoral head necrosis using 99mTc-Cys-Annexin V-based apoptosis imaging in a rabbit model
by: Xiaolong Wang, et al.
Published: (2020-12-01)